Medical Moment Two: Multifaceted Challenges in Medical Therapy Optimization during Episodes of Worsening HFrEF

Initiating and optimizing in-hospital guideline-directed medical therapies (GDMT) remains a challenge for clinicians treating patients with worsening HFrEF. Join Drs. Muthiah Vaduganathan and Michelle Kittleson, as they discuss opportunities and strategies to employ evidence-based therapies to address these challenges.


Supported through an independent educational grant from Merck.

Target Audience

Cardiologists and primary care physicians, alongside their interprofessional heart failure care team of nurse practitioners (NPs) and physician assistants (PAs).

Learning Objectives

  • Appraise the unique distinctions of HFrEF and how this impacts guideline-directed medical therapy (GDMT).
  • Examine recently-reported results from the VICTORIA trial, with an incisive emphasis on how novel pharmacologic approaches (sGC stimulation) can reduce heart failure hospitalization and readmission rates in patients with evidence of clinical worsening.

Additional Information

AttachmentSize
Handout2.44 MB
References457.56 KB
General Information1.95 MB
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Course opens: 
05/10/2021
Course expires: 
05/10/2022
Rating: 
0
On-Demand Enduring Activity
United States

Muthiah Vaduganathan, MD, MPH (Chair)
Instructor in Medicine
Harvard Medical School
Brigham and Women’s Hospital
Cardiovascular Medicine
Boston, Massachusetts

Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications. 

Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media / CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.

 

Michelle M Kittleson, MD, PhD
Professor of Medicine
Department of Cardiology, Smidt Heart Institute
Cedars-Sinai Medical Center
Los Angeles, California

 

Michelle Kittleson, MD, PhD is Director of Education in Heart Failure and Transplantation, Director of Heart Failure Research, and Professor of Medicine at the Smidt Heart Institute, Cedars-Sinai.  She is Deputy Editor of the Journal of Heart and Lung Transplantation, on Guideline Writing Committees for the American College of Cardiology (ACC)/American Heart Association and is the Co Editor-in-Chief for the ACC Heart Failure Self-Assessment Program.  Her essays have appeared in the New England Journal of Medicine, Annals of Internal Medicine, and JAMA Cardiology and poems in JAMA and Annals of Internal Medicine.


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.

Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa. He also receives grant/research support from Amgen, AstraZeneca, and Boehringer Ingelheim and is on the speakers' bureau for Novartis and Roche Diagnostics.

Speakers:
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for American Regent, Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa. He also receives grant/research support from Amgen, AstraZeneca, and Boehringer Ingelheim and is on the speakers' bureau for Novartis and Roche Diagnostics.

Michelle M Kittleson, MD, PhD–has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewers:
Terri Cook, PharmD, BCPC, AACC–has no relevant financial relationships to disclose in relation to the content of this activity.

Ravi B Patel, MD, MSc–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 


 

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™ per webinar. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Please login or register to take this course.